Interventional Radiology / Interventional Oncology / Latest Evidence / Target Study

 

 

colored background

The TARGET Study

A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.​

Watch The TARGET Study Video

Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolisation of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0

 


Study Objective

Establish the relationships between:

  • Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
  • Tumour absorbed dose (TAD) and Objective Response Rate (ORR)
  • TAD and Overall Survival (OS)

 

Study Design

Key Patient Characteristics

  • Mainly Intermediate and Advanced HCC: 33% BCLC B and 55% BCLC C
  • 7cm median target lesion
  • 33% PVT

Dosimetry Approach

  • Investigator review of patient chart and dosimetry calculation
  • Retrospective dosimetry evaluation with multi-compartment approach using Simplicit90Y™ personalised dosimetry software to determine TAD and NTAD

 

Results

Target Trial Results
Target Trial Results

Tumour Absorbed Dose Was Predictive of Response1,2

Tumor Absorbed Dose Was Predictive of Response
Tumor Absorbed Dose Was Predictive of Response

Tumour Absorbed Dose Was Predictive of Overall Survival

Tumor Absorbed Dose Was Predictive of Overall Survival
Tumor Absorbed Dose Was Predictive of Overall Survival

Low Rate of ≥ Grade 3 Hyperbilirubinemia Confirms Safety of TARGET Study

Low rate of ≥ Grade 3 hyperbilirubinemia
Low rate of ≥ Grade 3 hyperbilirubinemia
The TARGET Study Patient Characteristics 1.
 
The TARGET Study Patient Characteristics 2.
Learn more about our Latest Evidence
colored background

Study Takeaways

Deliver the highest dose to the tumour that is safely possible to maximise patient response and improve survival
Predictable results across 8 countries using multi-compartmental dosimetry using Simplicit90Y personalised dosimetry software
Like the LEGACY study and DOSISPHERE-01 trial results, the TARGET study reinforces the association between higher tumour absorbed dose and clinical outcomes
THERASPHRER™

Perform SIRT with TheraSphere™

Explore
SIMPLICIT<sup>90</sup>Y™

SIMPLICIT90Y™

Embrace Y90
SIRT Personalised Dosimetry
Explore
Physician Education

Virtual Events

Virtual Events

View our latest virtual symposia and webinars on interventional oncology topics. 
Explore Now
Stay up to date

Stay up to date

Stay up to date

Receive emails about the latest interventional oncology news, innovations and events.
Sign up
Top